Peak expiratory flow as a screening tool to detect airflow obstruction in a primary health care setting

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 674-680

  Tian, J ^a   Zhou, Y ^a   Cui, J ^a   Wang, D ^b   Wang, X ^c   Hu, G ^a   Tian, Y ^a   Jiang, Y ^a   Zheng, J ^a   Wang, J ^a,d   Zhong, N ^a   Ran, Pixin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Second Hospital of Liwan District of Guangzhou   (China)

^c First Municipal Hospital of Shaoguan   (China)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Airflow obstruction; COPD; PEF; Screening

Indexed keywords

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOWMETER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GOLD INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; GOLD INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE PLUS SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; PEAK EXPIRATORY FLOW; PREDICTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REFERENCE VALUE; REGRESSION ANALYSIS; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPIROMETRY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; AIRWAY OBSTRUCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; QUESTIONNAIRES; REFERENCE VALUES; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SPIROMETRY;

EID: 84859712502     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0429     Document Type: Article

References (33)

1. Global Initiative for Chronic Obstructive Lung Disease. Update in chronic obstructive pulmonary disease 2008. Be thesda, MD, USA: GOLD, 2008. http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2008 Accessed January 2012.
2. Lopez A D, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397-412. (Pubitemid 43180921)
3. Murray C J L, Lopez A D, Black R, et al. Global burden of disease 2005: call for collaborators. Lancet 2007; 370: 109-110. (Pubitemid 47042879)
4. Mathers C D, Roncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
5. Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 2007; 176: 753-760. (Pubitemid 47598476)
6. Mannino D M, Gagnon R C, Petty T L, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160: 1683-1689. (Pubitemid 30367908)
7. de la Iglesia F, Diaz J L, Pita S, et al. Peak expiratory low rate as predictor of inpatient death in patients with chronic obstructive pulmonary disease. South Med J 2005; 98: 266-272. (Pubitemid 40381702)
8. Emerman C L, Cydulka R K. Use of peak expiratory low rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1996; 27: 159-163. (Pubitemid 26055075)
9. Murata G H, Lium D J, Busby H K, et al. Precision and accuracy of self-measured peak expiratory low rates in chronic obstructive pulmonary disease. South Med J 1998; 91: 919-924. (Pubitemid 28476290)
10. Miller M R, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
11. Enright P L, Studnicka M, Zielinski J. Spirometry to detect and manage chronic obstructive pulmonary disease and asthma in the primary care setting. Eur Respir Mon 2005; 31: 1-14.
12. Ip M S, Ko F W, Lau A C, et al.; Hong Kong Thoracic Society. Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest 2006; 129: 384-392.
13. Quanjer P H, Tammeling C J, Cotes J E, et al. Lung volumes and forced ventilatory flows. Report Working Party 'Standardization of lung function tests' of ECSC. Eur Respir J 1993; 16: 5-40.
14. Zheng J, Zhong N. Normative values for pulmonary function testing in Chinese adults. Chin Med J (Engl) 2002; 115: 50-54. (Pubitemid 34130435)
15. Zheng J P, Yang L, Wu Y M, et al. The efficacy and safety of combination salmeterol (50 μg)/fluticasone propionate (500 μg) inhalation twice daily via Accuhaler in Chinese patients with COPD. Chest 2007; 132: 1756-1763.
16. Zheng J P, Kang J, Huang S G, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo controlled study. Lancet 2008; 371: 2013-2018. (Pubitemid 351799858)
17. Quanjer P H, Lebowitz M D, Gregg I, et al. Peak expiratory flow: conclusions and recommendations of a Working Party of the European Respiratory Society. Eur Respir J Suppl 1997; 24: 2S-8S.
18. Buist A S, Vollmer W M, Sullivan S D, et al. The Burden of Obstructive Lung Disease initiative (BOLD): rationale and design. COPD 2005; 2: 277-283. (Pubitemid 40993302)
19. Price D B, Tinkelman D G, Halbert R J, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006; 73: 285-295. (Pubitemid 43739190)
20. Price D B, Tinkelman D G, Nordyke R J, et al. Scoring system and clinical application of COPD diagnostic questionnaires. Chest 2006; 129: 1531-1539. (Pubitemid 43894982)
21. Zhong N, Zhang Y, Yu M, et al. [Peak expiratory flow in normal subjects and asthma]. Zhonghua Jie He He Hu Xi Za Zhi 1985; 8: 138-141. [Chinese]
22. Nunn A J, Gregg I. New regression equations for predicting peak expiratory flow in adults. BMJ 1989; 298: 1068-1070. (Pubitemid 19113984)
23. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
24. Pauwels R A, Lofdahl C G, Laitinen L A, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953. (Pubitemid 29288270)
25. National Heart, Lung and Blood Institute. Morbidity and mortality: chart book on cardiovascular, lung, and blood diseases. Bethesda, MD, USA: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1998.
26. Sin D D, Stafinski T, Ng Y C, et al. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med 2002; 165: 704-707. (Pubitemid 34194761)
27. Perez-Padilla R, Vollmer W M, Vázquez-García J C, et al. Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease? Int J Tuberc Lung Dis 2009; 13: 387-393.
28. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ 2003; 327: 653-654. (Pubitemid 37153559)
29. 1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest 2006; 130: 200-206.
30. 1 and peak expiratory flow in patients with airways obstruction is poor. Chest 2006; 130: 1454-1461.
31. 1 are poorly correlated in an elderly population. Chest 2007; 131: 1494-1499.
32. Johannessen A, Lehmann S, Omenaas E R, et al. Postbronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 2006; 173: 1316-1325. (Pubitemid 43900705)
33. Mu K J, Liu S W. Nationwide normal values of lung function. Beijing, China: Peking Union Medical College and Beijing Medical University, 1990.